AML Molecular Profile

, , ,

Detects  mutations in key genes recurrently mutated in acute myeloid leukemia (AML). DNA sequence of targeted regions of the ASXL1, BCOR, CEBPA, CSF3R, DNMT3A, EZH2, IDH1, IDH2, KIT, KRAS, NPM1, NRAS, PHF6, PTPN11, RAD21, RUNX1, SF3B1, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, and ZRSR2 genes is determined using next-generation sequencing (NGS) technology.

/by

ABL1 Kinase Domain Mutation

, , , ,

Detects ABL1 kinase domain mutations in patients with BCR-ABL1-positive chronic myelogenous leukemia (CML) or acute lymphoblastic leukemia (ALL). RNA is isolated, reverse transcribed to complementary DNA (cDNA), and the DNA sequence of targeted regions of ABL (exons 4, 6-7) is determined using next-generation sequencing (NGS) technology. Analysis includes detection of the common T315I mutation.

/by

COMPASS® Blood Evaluation

, , , , , ,

Includes COMPASS® consultation report, clinical pathology evaluation, blood morphology (up to 10 cytochemical stains), flow cytometry (up to 40 antibodies), cytogenetics and/or fluorescent in situ hybridization (FISH) (up to 14 probes), and molecular tests as medically necessary.

/by